21320-81-0

Upstream product

• 108-86-1 bromobenzene 
• 24393-61-1 ethyl (E)-3-(4-nitrophenyl)-2-propenoate 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 1144-74-7 4-nitrobenzophenone 

Downstream Products

• 21316-11-0 N--p-nitro-α-phenyl-zimtsaeureamid 
• 21316-16-5 p-Nitro-β-phenyl-zimtsaeure-p-fluorsulfonyl-anilid 
• 188913-58-8 (E)-2-hydroxy-5-[[4-[3-[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]-1-piperidinyl]-3-oxo-1-phenyl-1-propenyl]phenyl]azo]benzoic acid 
• 188913-58-8 (Z)-2-hydroxy-5-[[4-[3-[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]-1-piperidinyl]-3-oxo-1-phenyl-1-propenyl]phenyl]azo]benzoic acid 
• 188913-63-5 1-[4-(2-methyl-imidazo[4,5-c]pyridin-1-ylmethyl)-piperidin-1-yl]-3-(4-nitro-phenyl)-3-phenyl-propenone 
• 179173-99-0 cis-1-[[1-[3-(4-Aminophenyl)-3-phenylpropenoyl]-4-piperidyl]methyl]-1H-2-methylimidazo[4,5-c]pyridine 
• 179173-55-8 UR 12715 
• 17683-99-7 E/Z-3-(4-nitrophenyl)-3-phenylpropenoic acid 

Relevant academic research and scientific papers

Pd nanoparticles catalyzed stereospecific synthesis of β-aryl cinnamic esters in ionic liquids

Reaction of the catalyst 1 or Pd(OAc)2 with tetrabutylammonium acetate, dissolved in tetrabutylammonium bromide, leads to a fast formation of Pd nanoparticles which efficiently catalyze the stereospecific reaction of cinnamates with aryl halides to give β-aryl-substituted cinnamic esters. The role of tetrabutylammonium acetate is crucial in determining the formation of nanoparticles and stereospecificity of the C-C coupling process.

PPAR AGONIST COMPOUNDS, PREPARATION AND USES

The present invention relates to novel PPAR agonist compounds as well as pharmaceutical compositions containing them. The compounds according to the invention are of quite particular therapeutic interest, notably for treating diabetes and/or dyslipidemias, as well as for preventing cardiovascular pathologies.

Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity

This paper describes the synthesis of a series of azo compounds able to deliver 5-aminosalicylic acid (5-ASA) and a potent platelet activating factor (PAF) antagonist in a colon-specific manner for the purpose of treating ulcerative colitis. We found it p